| Literature DB >> 27077656 |
Nadia P Castro1, Anand S Merchant2, Karen L Saylor1, Miriam R Anver3, David S Salomon1, Yelena G Golubeva3.
Abstract
Laser capture microdissection (LCM) of tissue is an established tool in medical research for collection of distinguished cell populations under direct microscopic visualization for molecular analysis. LCM samples have been successfully analyzed in a number of genomic and proteomic downstream molecular applications. However, LCM sample collection and preparation procedure has to be adapted to each downstream analysis platform. In this present manuscript we describe in detail the adaptation of LCM methodology for the collection and preparation of fresh frozen samples for NanoString analysis based on a study of a model of mouse mammary gland carcinoma and its lung metastasis. Our adaptation of LCM sample preparation and workflow to the requirements of the NanoString platform allowed acquiring samples with high RNA quality. The NanoString analysis of such samples provided sensitive detection of genes of interest and their associated molecular pathways. NanoString is a reliable gene expression analysis platform that can be effectively coupled with LCM.Entities:
Mesh:
Year: 2016 PMID: 27077656 PMCID: PMC4831786 DOI: 10.1371/journal.pone.0153270
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Pathology annotations of target area and documentation of carcinoma dissection by laser cutting.
(A) Target area, carcinoma (a), was annotated by study pathologist on a digital image of reference H&E section of mammary gland (b) by green line (arrow); (B) View of LCM section with target area (a) on the dissecting screen of MMI CellCut microdissection instrument; (C) Dissecting screen view of the carcinoma area with the laser cut path (arrow); (D) Dissecting screen view of carcinoma area after retrieval of target cutout. A: Scale bar corresponds to 650 μm; B-D: Scale bars correspond to 300 μm.
Fig 2Documentation of lung metastasis removal from a mouse lung parenchyma by laser cutting.
(A) Dissecting screen view of metastasis (a) in a mouse lung parenchyma (b); (B) Dissecting screen view of lung metastasis with the laser cut path (arrow); (C) View of LCM target cutout on the collection cap. Scale bars correspond to 100 μm.
LCM Staining Protocol.
| Staining protocol step | Reagents | Duration | Temperature | Reference Image |
|---|---|---|---|---|
| Fixation | 100% ethanol | 30 sec | -20°C | |
| OCT removal I | MethylGreen | 20 sec | RT | |
| OCT removal II | MethylGreen (1000μl) with Protect RNA (4 μl) | 20 sec | RT | |
| Rinse | 100% ethanol | 10 sec | RT | |
| Stain | Cresyl Violet Acetate | 30 sec | RT | |
| Dehydration I | 100% ethanol | 30 sec | RT | |
| Dehydration II | 100% ethanol | 30 sec | RT | |
| Clearing I | Xylene | 2 min | RT | |
| Clearing II | Xylene | 3 min | RT | |
| Drying I | Air dry in the hood | 5 min | RT | |
| Drying II | Desiccator | 1–4 hour | RT |
1, 2 Mallinckrodf Baker Inc., Phillipsburg, NJ, USA
3 Vector Laboratories, Inc., Burlingame, CA, USA
4, 5 Sigma, Saint Louis, MO, USA
6 VWR International, Rednor, PA, USA
7 EMD Chemicals, Inc. Cincinnati, OH
Evaluation of Tissue Integrity, LCM Workflow Suitability, Quality and Yield of RNA in LCM Targets.
| Sample | Time in desiccator (hours) | Total collectedtissue area (mm²) | Total RNA per mm² of tissue (ng) | Approximated area required for collection of 100ng total RNA (mm²) | RNA Integrity number (RIN) Mean ±SD (n = 2) |
|---|---|---|---|---|---|
| Tumor 1 block, mixed targets, no LCM | 0 | 40 (one frozen section) | 37 | 2.7 | 9.6 ± 0.1 |
| Tumor 2 block, mixed targets, no LCM | 0 | 48 (one frozen section) | 28 | 3.4 | 9.8 ± 0.1 |
| Mammary gland block, mixed targets, no LCM | 0 | 56.3 (one frozen section) | 17 | 5.7 | 9.7 ± 0.2 |
| Lung block, mixed targets, no LCM | 0 | 90.6 (one frozen section) | 5 | 21.7 | 9.1 ± 0.3 |
| Metastatic lung block, mixed targets, as described in method section, no LCM | 0 | 140 (one frozen section) | 8 | 12.2 | 9.8 ± 0.2 |
| Carcinoma 1, LCM | 3.5 | 4 | 39 | 2.5 | 8.4 ± 0.1 |
| EMT 1, LCM | 3 | 7.4 | 30 | 3 | 8.5 ± 0.1 |
| Carcinoma 2, LCM | 5 | 6.8 | 54 | 2 | 8.5 ± 0.1 |
| Mammary gland, LCM | 4.5 | 27.4 | 18 | 5 | 8.3 ± 0.1 |
| Lung parenchyma, LCM | 4 | 63.7 | 7 | 14 | 7.6 ± 0.4 |
| Lung metastasis, LCM | 4 | 20.5 | 38 | 2.5 | 9.1 ± 0.2 |
Fig 3Representative Agilent electropherograms of high quality RNA retrieved from the control sections and corresponding LCM targets.
(A, C, F) Frozen section of normal mammary gland (A), primary mammary tumor (C) and lung metastasis (F) placed directly in lysis buffer for RNA extraction. (B) LCM sample of normal mammary tissue; (D, E) LCM cell populations of primary mammary tumor: carcinoma (D) and EMT (E); (G) LCM sample of lung metastasis.
Pearson Correlation Scores for Individual Sample Groups Between NanoString and Microarray (p-value < 0.001).
| Sample Group | Pearson Score |
|---|---|
| Primary Tumor | 0.80 |
| Lung Metastasis | 0.81 |
| Normal Mammary Gland | 0.79 |
| Normal Lung | 0.80 |
Fig 4Unsupervised hierarchical clustering of normal mammary gland versus primary tumor.
Scaled down representation of the entire cluster is based on 24 genes differentially expressed between normal mammary gland (NMG) and primary mammary tumors (PT). Each row represents a single gene and each column represents a sample. Red color indicates upregulation, green color—downregulation, and black color—no change in expression level compared with the reference sample.
Fig 5Unsupervised hierarchical clustering of carcinoma versus EMT.
Scaled down representation of the entire cluster is based on 17 genes differentially expressed between carcinoma (epithelial-like areas) and EMT (spindle-like areas). Each row represents a single gene and each column represents a sample. Red color indicates upregulation, green color—downregulation, and black color—no change in expression level compared with the reference sample. EMT: Epithelial-Mesenchymal transition.